8-K/A: CannaPharmaRX Secures Multi-Million Dollar Supply Agreement with Israeli Cannabis Leader Cantek

CannaPharmaRX has finalized a supply agreement with Cantek, a leading Israeli medical cannabis distributor, for a minimum of 1,000 kg of cannabis annually.

Summary

• CannaPharmaRX has entered into a supply agreement with D.N.S. Cantek 2019 Ltd., an Israeli company, to supply a minimum of 1,000 kg of cannabis per year.
• The agreement is for an initial term of three years, with automatic renewal for additional three-year terms unless either party provides notice of non-renewal.
• The price of the cannabis is set at $2.75 CDN per gram for minimum orders of 50kg, but may vary based on quality and market prices.
• CannaPharmaRX will be responsible for shipping and insurance costs, while the buyer is responsible for all taxes related to the sale, shipment, or use of the goods.
• The agreement includes detailed specifications for the cannabis, including appearance, color, odor, and various test parameters.
• The initial shipment is expected to begin in late Q1 2024, after securing all necessary export and import permits and licenses.

Sentiment

Score: 8

Explanation: The document indicates a positive development for CannaPharmaRX with a significant supply agreement, suggesting strong growth potential and market validation. The agreement is well structured with standard industry clauses.

Positives

• The agreement provides CannaPharmaRX with access to the growing Israeli cannabis market.
• The minimum annual supply of 1,000 kg provides a stable revenue stream.
• The agreement includes a most favored buyer clause, ensuring Cantek receives the best terms offered by CannaPharmaRX.
• The agreement includes a 90-day warranty period for the goods.
• Cantek's strong distribution network in Israel provides a reliable channel for CannaPharmaRX's products.

Negatives

• The agreement includes a clause that allows the buyer to cancel the portion of a purchase order if the shipment is delayed by more than 20 days.
• The agreement includes a clause that allows the supplier to terminate the agreement if their lease of the facility is terminated.
• The agreement includes a clause that allows the supplier to terminate the agreement if the buyer fails to pay any amount when due.

Risks

• Delays in shipment could lead to order cancellations.
• The termination of the supplier's facility lease could lead to the termination of the agreement.
• Failure of the buyer to make payments could lead to the termination of the agreement.
• The agreement is subject to various laws and regulations, which could change and impact the agreement.
• The agreement is subject to force majeure events, which could impact the ability of the parties to fulfill their obligations.

Future Outlook

CannaPharmaRX plans to expand its cannabis brands and leverage its science in key international markets, with this agreement being a major step forward in ensuring product is pre-sold prior to planting and harvesting.

Management Comments

• Dean Medwid, CEO of CannaPharmaRX, stated that the agreement provides a great opportunity to expand their cannabis brands and industry-leading science in a key international market.
• Dean Medwid also noted that the agreement validates their position in the world's cannabis market and is a major step towards pre-selling their product.

Industry Context

This agreement aligns with the growing global trend of international cannabis trade and the increasing demand for medical cannabis in countries like Israel. It positions CannaPharmaRX to capitalize on the expanding market and establish a strong international presence.

Comparison to Industry Standards

• The agreement's minimum annual supply of 1,000 kg is a significant volume, comparable to other large-scale supply agreements in the cannabis industry.
• The pricing structure, while subject to market conditions, is within the typical range for wholesale cannabis supply agreements.
• The 90-day warranty period is a standard practice in the industry, providing a level of assurance to the buyer.
• The most favored buyer clause is a common practice in supply agreements, ensuring the buyer receives competitive terms.
• Cantek's position as a leading medical cannabis enterprise in Israel is similar to other major distributors in established cannabis markets.

Stakeholder Impact

• Shareholders will likely view this agreement positively as it represents a significant revenue opportunity and market expansion.
• Employees may see this as a positive development, potentially leading to job security and growth opportunities.
• Customers of Cantek will have access to CannaPharmaRX's cannabis products.
• Suppliers of CannaPharmaRX may see increased demand for their products.
• Creditors may view this agreement as a positive sign of the company's financial stability.

Next Steps

• CannaPharmaRX will begin the initial shipment of cannabis to Cantek in late Q1 2024.
• CannaPharmaRX will continue to develop its cannabis markets internationally.
• CannaPharmaRX will continue discussions with other companies regarding potential acquisitions.

Key Dates

Keywords

cannabis, supply agreement, medical cannabis, CannaPharmaRX, Cantek, Israel, export, import, distribution, production